Ara
Toplam kayıt 9, listelenen: 1-9
Outcomes of surveillance VS. adjuvant chemotherapy for patients with STAGE IA and IB NON-seminomatous testicular germ-cell tumors
(American Society of Clinical Oncology, 2016)
...
Pertuzumab, trastuzumab and taxane combination for visceral organ metastatic patients: Real life practice results
(Oxford University Press, 2018)
...
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors
(Springer, 2017)
Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active ...
Treatment preferences in stage IA and IB testicular seminoma: Multicenter study of anatolian society of medical oncology
(Springer, 2015)
Approximately 75 % of patients with testicular seminoma present with stage I disease, and the probability of long-term survival approaches 100 %. However, the standard adjuvant treatment for stage I seminoma patients remains ...
Merkel cell carcinoma in Turkey: A multicentric study
(Wolters Kluwer Medknow Publications, 2021)
Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of ...
The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A multi-center, prospective registry study
(Springer, 2021)
Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) ...
Comparison of response and survival of first-line crizotinib therapy according to EML-4 ALK fusion variants in advanced non-small cell lung cancer patients: A Turkish Oncology Group study
(Zerbinis Publications, 2021)
Purpose: In the literature there are conflicting data about the treatment efficacy of anaplastic lymphoma kinase (ALK) translocation positive non-small cell lung cancer (NSCLC) patients according to ALK fusion variants. ...
Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: A multicenter real-life HER2PATH study
(Taylor & Francis Ltd, 2023)
AimTo investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC) ...